美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

KraneShares China Alpha Index ETF

33.14

+0.07000.21%

成交量：178

成交額：5,919

市值：331.42萬

市盈率：- -

高：33.14

開：33.09

低：33.09

收：33.07

52周最高：40.84

52周最低：30.00

股本：10.00萬

流通股本：10.00萬

量比：0.35

換手率：0.18%

股息：10.72

股息率：32.33%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

港股異動 | 夢金園(02585)尾盤漲近4% 夢金園2026三大新品系列發布面向年輕消費群體佈局

港股異動 | 翼菲科技(06871)尾盤漲近9% 上半年本體機器人銷售量表現強勁海外收入按年大幅增加318.5%

【新股IPO】海柔創新再推港股IPO進程龍頭光環下暗藏盈利與負債困境

港股異動 | 亮晴控股(03774)盤中升逾31% 公司轉主板上市兩月有餘本月初正式進入港股通名單

港股異動 | 德適-B(02526)最高升逾14% 與安診兒訂立合作框架協議共同探索「醫療數據資產化」核心方向

新股前瞻|攻克抗生素耐藥性難題，普萊醫藥闖關港股能否獲市場下注？

港股異動 | 百奧賽圖-B(02315)升逾6% 行業景氣度持續高漲動物模型及臨床前藥效業務維持高增

港股異動 | 沛嘉醫療-B(09996)升逾3% GeminiOne®經導管緣對緣修復系統註冊申請獲國家藥監局批准

港股異動 | 華寶國際午後升逾12%，國內HNB監管框架進一步成型，煙用香精業務有望受益

港股異動 | 三葉草生物-B(02197)午後升逾6% 呼吸道聯合疫苗澳洲II期臨床獲積極數據

港股諾誠健華升逾15%，近日PSMA/STEAP1雙抗ADC ICP-B381獲批臨床。

港股異動 | 映恩生物-B升逾9%，DB-1311聯用Pumitamig WCLC摘要披露，一線SCLC ORR達92.3%

港股異動 | 科倫博泰生物(06990)升逾3% POLARIS-1臨床試驗2期部分取得陽性結果並已啓動3期臨床

港股異動 | 君實生物(01877)升逾3% 兩款雙特異性抗體新藥均計劃在年內啓動關鍵III期臨床研究

港股異動 | 翰森製藥(03692)漲近4% 瑞康立伏妥塔單抗的中位OS達到18.5個月

港股異動 | 零跑汽車(09863)午後漲近6% 連續兩月銷量突破10萬輛公司上調海外銷量指引

港股異動丨俊知集團一度飆升超70%，擬購光纖產品產銷公司

港股芯片股午後走低

港股芯片股午後走低，江波龍跌超10%，兆易創新、天數智芯跌超5%，瀾起科技、壁仞科技跌超4%。

港股異動 | 煤炭股普遍走低動力煤港口價格顯出回落跡象機構指市場供應偏緊格局未改

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/KCAI/news?page=14"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"KCAI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KCAI\",,,,,undefined,":{"symbol":"KCAI","market":"US","secType":"STK","nameCN":"KraneShares China Alpha Index ETF","latestPrice":33.14,"timestamp":1789675200000,"preClose":33.07,"halted":0,"volume":178,"delay":0,"changeRate":0.0021167221046265584,"floatShares":100005,"shares":100005,"eps":0,"marketStatus":"盤前交易","change":0.07,"latestTime":"09-18 05:57:49 EDT","open":33.09,"high":33.14,"low":33.09,"amount":5919,"amplitude":0.001512,"askPrice":52.69,"askSize":100,"bidPrice":13.33,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":33.14,"sharesOutstanding":250002,"nav":33.29,"aum":3329125.04,"dividendRate":0.323349,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.09,"preClose":33.14,"latestTime":"16:10 EDT","volume":6,"amount":198.84,"timestamp":1789675804216,"change":-0.05,"changeRate":-0.001509,"amplitude":0},"volumeRatio":0.34984287043323614},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KCAI\",,,,,undefined,":{"symbol":"KCAI","floatShares":100005,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.34984287043323614,"shares":100005,"dividePrice":10.7158,"high":33.14,"amplitude":0.001512,"preClose":33.07,"low":33.09,"week52Low":30,"pbRate":"--","week52High":40.84,"institutionHeld":0,"latestPrice":33.14,"eps":0,"divideRate":0.323349,"volume":178,"delay":0,"ttmEps":0,"open":33.09,"prevYearClose":30.48,"prevWeekClose":33.22,"prevMonthClose":33.259,"prevQuarterClose":32.15,"fiveDayClose":33.3209,"twentyDayClose":32.81,"sixtyDayClose":32.6999},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KCAI\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"KCAI","amount":0.080552,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"KraneShares China Alpha Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2025-12-31"},{"date":"2025-12-22","symbol":"KCAI","amount":10.716664,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares China Alpha Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KCAI","amount":0.59272,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares China Alpha Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KCAI\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-18","value":0.59272,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-23","value":10.716664,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2025-12-31","value":0.080552,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KCAI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KCAI\",pageSize:20,pageCount:14,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667277656","title":"港股異動 | 夢金園(02585)尾盤漲近4% 夢金園2026三大新品系列發布 面向年輕消費群體佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2667277656","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667277656?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:06","pubTimestamp":1789373210,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，梦金园尾盘涨近4%。消息面上，9月3日，以“好运交织·梦启新境”为主题的梦金园2026新品发布会在山东黄金珠宝智能制造中心隆重召开。据介绍，此次发布会围绕产品年轻化、时尚化方向展开，是梦金园面向年轻消费群体的一次新品布局。梦金园中期业绩公告显示，上半年实现收入101.75亿元；归母净利润1951.7万元，同比实现扭亏为盈。梦金园称，下一步将聚焦渠道转型、高端品牌升级、智能制造迭代、海外市场发力四大核心战略。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02585","KCAI","VXUS","BK1227","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656272","title":"港股異動 | 翼菲科技(06871)尾盤漲近9% 上半年本體機器人銷售量表現強勁 海外收入按年大幅增加318.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656272","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656272?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:03","pubTimestamp":1789372994,"startTime":"0","endTime":"0","summary":"消息面上，近期，翼菲科技发布截至2026年6月30日止6个月中期业绩，报告期内，本集团实现收入1.86亿元，同比增长58.0%；毛利率保持稳定于23.7%，同比增长0.6%。公告称，收入增长主要源于本体机器人销售量的强劲增长。国证国际发布研报称，翼菲科技2026年上半年机器人本体收入7803万元，占比由28.5%提升至41.9%，同比增加132.5%。该行认为，翼菲科技作为轻工业机器人龙头，机器人本体放量与海外市场突破双轮驱动收入高增，具身智能商业化打开长期成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PBOT","KOMP","ROBO","BK4588","06871","KCAI","BK1183","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667493656","title":"【新股IPO】海柔創新再推港股IPO進程 龍頭光環下暗藏盈利與負債困境","url":"https://stock-news.laohu8.com/highlight/detail?id=2667493656","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667493656?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:54","pubTimestamp":1789372472,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所9月13日披露，海柔创新更新招股书，继续推进港股IPO上市进程，高盛、中信证券为联席保荐人。依托先发技术优势与持续迭代的产品体系，海柔创新在全球ACR市场的龙头地位持续巩固。截至2026年7月末，海柔创新的赎回负债达52.76亿元，占流动负债比例超过66.8%，而这笔负债每年产生的利息就将近2亿元，正持续侵蚀利润。海柔创新虽然在全球ACR市场占据超过30%的份额，但行业仍处于快速演变之中。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/YzZkNGQ5YjgxMTczNjIxODI3MDA4NQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YzZkNGQ5YjgxMTczNjIxODI3MDA4NQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991562","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRHC","BK4588","IPOS","VXUS","KCE","REDS","BK4127","BK4585","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667492656","title":"港股異動 | 亮晴控股(03774)盤中升逾31% 公司轉主板上市兩月有餘 本月初正式進入港股通名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2667492656","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667492656?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:52","pubTimestamp":1789372341,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亮晴控股盘中涨超31%。消息面上，上交所近期宣布调整沪港通下港股通标的，亮晴控股正式进入港股通名单，已于9月7日起生效。值得注意的是，6月30日，亮晴控股成功从GEM转至主板上市。公司转主板两月有余便进入港股通名单，有助于进一步优化投资者结构、提升股票流动性及企业品牌价值。值得一提的是，今年7月，亮晴控股“AI抗衰老”平台开发启动，委聘香港AI企业Sunseeker开发模型。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK4585","03774","BK4588","VXUS","IPOS","BK1215","FLHK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656224","title":"港股異動 | 德適-B(02526)最高升逾14% 與安診兒訂立合作框架協議 共同探索 「醫療數據資產化」 核心方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656224","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656224?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:49","pubTimestamp":1789372174,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德适-B最高涨超14%，截至发稿，涨7.25%，报509港元，成交额7412.57万港元。消息面上，9月11日，德适-B发布公告，本公司与浙江省安诊儿医学人工智能科技有限公司(安诊儿)订立合作框架协议，围绕医学影像人工智能、基层影像云服务及医疗数据产品开展合作，合作期限自签订之日起为三年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK4585","KCAI","BK4588","02526","159891","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667765505","title":"新股前瞻|攻克抗生素耐藥性難題，普萊醫藥闖關港股能否獲市場下注？","url":"https://stock-news.laohu8.com/highlight/detail?id=2667765505","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667765505?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:36","pubTimestamp":1789371362,"startTime":"0","endTime":"0","summary":"近日，普莱医药向港交所主板递交上市申请，中信证券担任独家保荐人，这是公司继2月13日首次提交上市申请后的第二次递表。目前的治疗药物以唑类抗真菌药为主，但耐药性问题同样存在。目前该产品正在中国进行一项II期临床试验，且已获FDA批准在美国进行一项II期临床试验。整体来看，在全球抗生素耐药性问题日益严峻的背景下，抗菌肽作为新型抗感染药物具备广阔的市场前景。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","09939","BK4585","BK1574","BK4588","KCAI","VXUS","159938"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2667554306","title":"港股異動 | 百奧賽圖-B(02315)升逾6% 行業景氣度持續高漲 動物模型及臨床前藥效業務維持高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2667554306","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667554306?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:31","pubTimestamp":1789371077,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超6%，截至发稿，涨6.24%，报59.6港元，成交额8729.41万港元。消息面上，今年上半年，百奥赛图实现营收9.4亿元，同比增长51.6%；归母净利润2.4亿元，同比大增402%。与此同时，本月初，百奥赛图宣布与齐鲁制药达成全人纳米抗体分子非排他授权合作，支持神经领域创新药物开发。中邮证券指出，行业景气度持续高涨叠加海外拓展共振，动物模型+临床前药效业务维持高增。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","BK4585","VXUS","688796","BK0216","02315","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667563655","title":"港股異動 | 沛嘉醫療-B(09996)升逾3% GeminiOne®經導管緣對緣修復系統註冊申請獲國家藥監局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667563655","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667563655?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:18","pubTimestamp":1789370281,"startTime":"0","endTime":"0","summary":"消息面上，9月11日，沛嘉医疗-B发布公告，公司自主研发的GeminiOne经导管缘对缘修复系统近期已获中华人民共和国国家药品监督管理局批准其注册申请。GeminiOne获批标志着集团正式进入二尖瓣反流的商业化治疗领域，并代表集团在主动脉瓣狭窄及主动脉瓣反流治疗既有布局的基础上，进一步显著扩充其经导管瓣膜治疗产品组合。GeminiOne之EU MDR CE标志注册申请已提交，而美国早期可行性研究现正进行中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","KCAI","159891","09996","BK1583","BK4588","BK4585","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658043","title":"港股異動 | 華寶國際午後升逾12%，國內HNB監管框架進一步成型，煙用香精業務有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658043","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658043?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:17","pubTimestamp":1789370258,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华宝国际午后涨超12%。兴业证券指出，意见稿首次明确烟支、烟具和气溶胶具体要求，国内HNB监管框架进一步成型。东北证券指出，国内卷烟市场需求增长面临较大压力，因此HNB放开提上日程成为挽救国内烟草市场的必选项。加热卷烟国标公开征求意见，标志着中国HNB产业从“政策模糊期”迈入“规则明确期”。HNB和口含烟的发展带来新的香精需求，有利于公司烟用香精业务的发展。","market":"sh","thumbnail":"https://static.tigerbbs.com/2b916287cbff73b370c1a2e0a155be73","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/2b916287cbff73b370c1a2e0a155be73"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495549.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华宝国际午后涨超12%，国内HNB监管框架进一步成型，烟用香精业务有望受益","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1129","VXUS","BK1580","BK4585","00336","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667965362","title":"港股異動 | 三葉草生物-B(02197)午後升逾6% 呼吸道聯合疫苗澳洲II期臨床獲積極數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2667965362","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667965362?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:54","pubTimestamp":1789368871,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三叶草生物-B午后涨超6%。截至发稿，涨5.24%，报2.01港元，成交额548.61万港元。消息面上，三叶草生物近期宣布，其呼吸道联合疫苗候选产品SCB-1022和SCB-1033在澳大利亚老年人群中开展的II期临床试验获得积极初步数据。此外，公司已完成SCB-1022/1033相关抗原组分2000L生物反应器商业规模生产放大，并完成多个批次。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK4588","BK4585","02197","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667535356","title":"港股諾誠健華 升逾15%，近日PSMA/STEAP1雙抗ADC ICP-B381獲批臨床。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667535356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667535356?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:49","pubTimestamp":1789368572,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["KCAI","BK4585","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658657","title":"港股異動 | 映恩生物-B升逾9%，DB-1311聯用Pumitamig WCLC摘要披露，一線SCLC ORR達92.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658657","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658657?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:38","pubTimestamp":1789367907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超9%，截至发稿，涨8.48%，报183港元，成交额1.65亿港元。消息面上，世界肺癌大会更新了映恩生物与BioNTech共同开发的B7-H3 ADC BNT324/DB-1311联合PD-L1×VEGF-A双抗Pumitamig治疗晚期肺癌的Ib/II期数据：截至2026年7月7日，71例可评估小细胞肺癌患者整体客观缓解率为70.4%，其中一线92.3%、二线77.3%、三线及以上52.4%。","market":"sh","thumbnail":"https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495543.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物 DB-1311联用Pumitamig WCLC摘要披露，一线SCLC ORR达92.3%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","HK0000500386.USD","09606","BK4585","ORR","HK0000252152.HKD","KCAI","BK4588","LU2543165471.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658010","title":"港股異動 | 科倫博泰生物(06990)升逾3% POLARIS-1臨床試驗2期部分取得陽性結果 並已啓動3期臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658010","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658010?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:36","pubTimestamp":1789367775,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物涨超3%，截至发稿，涨3.35%，报480.8港元，成交额2.53亿港元。消息面上，近日，科伦博泰生物发布公告，公司的合作方Windward Bio AG已公布SKB378/WIN378用于治疗哮喘的POLARIS-1临床试验2期部分取得阳性的中期结果。POLARIS-1的3期部分已由Windward Bio启动，确定采用两种每年两次给药的剂量方案，旨在评估SKB378/WIN378对重度哮喘患者的年化哮喘急性发作率及其他关键疗效指标的影响。POLARIS-1的2期研究数据将在即将召开的医学会议上公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","BK4585","IBBJ","LU0196878994.USD","KCAI","MDTX","06990","IBBQ","PSYK","BK1161","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658586","title":"港股異動 | 君實生物(01877)升逾3% 兩款雙特異性抗體新藥均計劃在年內啓動關鍵III期臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658586","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:15","pubTimestamp":1789366522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物(01877)涨超3%，截至发稿，涨3.07%，报17.11港元，成交额1995.51万港元。消息面上，9月14日，君实生物在2026年半年度业绩说明会上披露核心创新药管线的最新研发进展。公司明确表示，两款备受关注的双特异性抗体新药均计划在2026年内启动关键的III期临床研究。其中，靶向CD20/CD3的双抗药物JS203将正式进入III期临床阶段；而另一款靶向PD-1/VEGF的双抗药物JS207目前正处于II期临床研究阶段，正在多个瘤种中积极开展与化疗、单抗及ADC等不同治疗手段的联合用药探索，并同样预计于2026年内启动III期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","01877","BK1161","BK1515","BK4588","KCAI","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667630269","title":"港股異動 | 翰森製藥(03692)漲近4% 瑞康立伏妥塔單抗的中位OS達到18.5個月","url":"https://stock-news.laohu8.com/highlight/detail?id=2667630269","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667630269?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:58","pubTimestamp":1789365528,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰森制药涨近4%，截至发稿，涨3.73%，报33.94港元，成交额2.05亿港元。消息面上，9月13日，翰森制药在2026世界肺癌大会首场主席论坛上，以最新突破性摘要形式口头报告自研B7-H3靶向ADC——瑞康立伏妥塔单抗的III期ARTEMIS-008研究期中结果。这次公布的数据，瑞康立伏妥塔单抗刷新了小细胞肺癌二线治疗最长总生存期纪录。具体看，瑞康立伏妥塔单抗的中位OS达到18.5个月，而托泊替康的中位OS是10.3个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","03692","KCAI","BK4585","BK4588","VXUS","BK1589","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667630605","title":"港股異動 | 零跑汽車(09863)午後漲近6% 連續兩月銷量突破10萬輛 公司上調海外銷量指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2667630605","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667630605?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:57","pubTimestamp":1789365435,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，零跑汽车午后涨近6%。消息面上，零跑汽车8月销量103129辆，同比增长80.7%，环比增长1.8%，连续两月销量突破10万辆并再创历史新高。中信建投则表示，公司积极上调海外销量指引至2026全年稳步完成海外销量15万辆，挑战20万辆；2027年海外销量目标35-40万辆。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","KCAI","BK1119","BK4585","VXUS","09863"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667302406","title":"港股異動丨俊知集團一度飆升超70%，擬購光纖產品產銷公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2667302406","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667302406?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:57","pubTimestamp":1789365421,"startTime":"0","endTime":"0","summary":"俊知集团(1300.HK)上午盘中一度飙升超70%至3.465港元，股价创6月以来新高，截至目前成交额放大至1.7亿港元。消息面上，公司宣布，拟收购青海中利光纤技术100%股权，代价4.55亿元。目标公司主要从事光纤预制棒、光纤及光纤接插件的生产及销售。而目标附属公司则主要从事光纤预制棒、光纤、光纤接插件的研究与开发。董事会预期，于签订《产权交易合同》后，收购事项将根据上市规则第14章构成公司的须予披露交易。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/14/20260914712863.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/14/20260914712863.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260914/32368841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4585","BK1506","BK4588","KCAI","01300","BK1149","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667163099","title":"港股芯片股午後走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2667163099","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667163099?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:52","pubTimestamp":1789365157,"startTime":"0","endTime":"0","summary":"港股芯片股午后走低","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873328636.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873328636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KCAI","XSEM","BK4585","VXUS","BERZ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667557630","title":"港股芯片股午後走低，江波龍跌超10%，兆易創新、天數智芯跌超5%，瀾起科技、壁仞科技跌超4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667557630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667557630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:47","pubTimestamp":1789364877,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["VXUS","BK4585","BK4588","BERZ","KCAI","XSEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667305630","title":"港股異動 | 煤炭股普遍走低 動力煤港口價格顯出回落跡象 機構指市場供應偏緊格局未改","url":"https://stock-news.laohu8.com/highlight/detail?id=2667305630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667305630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:42","pubTimestamp":1789364534,"startTime":"0","endTime":"0","summary":"消息面上，近期动力煤港口价格显出回落迹象，产地煤价涨跌互现。煤炭资源网数据显示，截至9月11日，秦皇岛港Q5500动力煤市场价报收于984元/吨，周环比上涨42元/吨，但9月11日环比下降1元/吨。国联民生证券认为，本轮下跌更多是对前期超涨的修正，市场供应偏紧格局未改。供给端安监高压持续，产地供给仍受限。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","KCAI","BK1538","VXUS","03668","161032","BK1178","00866","BK1225","01171","COAL","00639","BK4588","BK1594","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":34,"pageCount":14,"totalSize":674,"code":"91000000","status":"200"}]}}